Hanseatic Management Services Inc Alnylam Pharmaceuticals, Inc. Transaction History

Hanseatic Management Services Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 29, 2020	SELL	$121.19 - $165.49 $784,341 - $1.07 Million	-6,472 Closed	0 $0
Q2 2020 Aug 10, 2020	SELL	$104.21 - $156.44 $234,785 - $352,459	-2,253 Reduced 25.82%	6,472 $959,000
Q1 2020 Apr 22, 2020	BUY	$93.12 - $133.99 $218,459 - $314,340	2,346 Added 36.78%	8,725 $950,000
Q4 2019 Jan 29, 2020	BUY	$74.51 - $124.23 $475,299 - $792,463	6,379 New	6,379 $735,000
Q4 2018 Jan 29, 2019	SELL	$62.67 - $88.33 $15,416 - $21,729	-246 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $429,110 - $601,451	-4,903 Reduced 95.22%	246 $22,000
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $441 - $539	-5 Reduced 0.1%	5,149 $507,000
Q1 2018 May 02, 2018	SELL	$115.92 - $148.54 $1,622 - $2,079	-14 Reduced 0.27%	5,154 $614,000
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $14,082 - $17,217	123 Added 2.44%	5,168 $657,000
Q3 2017 Nov 07, 2017	SELL	$72.53 - $118.27 $186,764 - $304,545	-2,575 Reduced 33.79%	5,045 $593,000
Q2 2017 Aug 11, 2017	BUY	N/A	7,620	7,620 $608,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Hanseatic Management Services Inc, based on Form 13F filings with the SEC.

Stay updated on Hanseatic Management Services Inc with notifications on news.